|Bid||0.96 x 3000|
|Ask||1.06 x 500|
|Day's Range||1.0000 - 1.0400|
|52 Week Range||0.9000 - 2.0900|
|Beta (3Y Monthly)||2.13|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that its board of directors has appointed one new member. David Shapiro, M.D., Chief Medical Officer of Intercept Pharmaceuticals, Inc. (“Intercept”), will join Organovo’s board, effective immediately. Dr. Shapiro’s appointment increases the number of Organovo directors to eight.
Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that it has entered into a cell and tissue clinical sourcing agreement with the International Institute for the Advancement of Medicine (“IIAM”). Under the terms of the agreement, IIAM will provide Organovo with donated organs that have not been utilized for transplantation with high potential benefit for generating the cell-based building blocks for Organovo’s therapeutic liver tissue development program.
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019Second orphan designation anticipated in first half of calendar 2019Submit first.
Organovo Holdings, Inc. (ONVO) (“Organovo”) will host a conference call on Thursday, November 8, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal second-quarter 2019 operating and financial highlights. In advance of the call on November 8, 2018, Organovo will issue its fiscal second-quarter 2019 earnings press release, which will be available at http://www.organovo.com.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SAN DIEGO, Oct. 15, 2018 -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a.
Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that Chief Executive Officer, Taylor J. Crouch, is scheduled to speak at the Cell & Gene Meeting on the Mesa to be held October 3-5 in La Jolla, Ca. This conference is the largest partnering meeting organized specifically for the cell and gene therapy sector, providing the opportunity for participants to establish key relationships and accelerate business development. Organized by ARM and the Sanford Stem Cell Clinical Center at UC San Diego, the Cell & Gene Meeting on the Mesa is a three-day conference featuring three distinct parts, the program’s two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Organovo Holdings, Inc. (NASDAQ: ONVO ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 9, 2018 at 5:00 PM Eastern ...
On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), OpGen Inc. (NASDAQ: OPGN), and Organovo Holdings Inc. (NASDAQ: ONVO). On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 373,287 shares.
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on ONVO sign up now at www.wallstequities.com/registration. Durham, North Carolina headquartered IQVIA Holdings Inc.'s stock finished Wednesday's session 1.31% higher at $100.48 with a total trading volume of 968,866 shares. Over the last month and the previous three months, the Company's shares have advanced 4.93% and 2.19%, respectively.
Late-Breaking Poster Presented at The International Liver Congress SAN DIEGO and KALAMAZOO, Mich. , April 12, 2018 /PRNewswire/ -- Cirius Therapeutics announced today that it presented a late-breaking ...